NCTId,BriefTitle,Phase,SponsorName,success_rate,median_approval_year,mean_approval_year,pct10_approval_year,pct90_approval_year,earliest_approval_year,latest_approval_year
NCT04794101,Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene,PHASE3,"Janssen Research & Development, LLC",0.6473,2028.0,2028.2807044646995,2027.0,2029.0,2027,2031
NCT03584165,Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa,PHASE3,"NightstaRx Ltd, a Biogen Company",0.7119,2029.0,2029.1387835370135,2028.0,2030.0,2027,2031
NCT05926583,A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa,PHASE3,Janssen Pharmaceutical K.K.,0.649,2031.0,2030.871494607088,2030.0,2032.0,2029,2033
NCT05537220,Oral N-acetylcysteine for Retinitis Pigmentosa,PHASE3,Johns Hopkins University,0.7196,2031.0,2030.9459421901056,2030.0,2032.0,2029,2033
NCT06388200,A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa,PHASE3,Ocugen,0.6412,2032.0,2031.6294447910168,2031.0,2033.0,2029,2034
NCT06333249,A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE),PHASE2,Beacon Therapeutics,0.5628,2033.0,2033.1632906894101,2032.0,2034.0,2031,2035
NCT02065011,"A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of SAR421869 in Patients With Usher Syndrome Type 1B",PHASE2,Sanofi,0.5635,2033.0,2033.145519077196,2032.0,2034.0,2031,2035
NCT00999609,Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis,PHASE3,"Spark Therapeutics, Inc.",0.7189,2033.0,2032.6470997357073,2032.0,2034.0,2030,2035
NCT04356716,Sildenafil for Treatment of Choroidal Ischemia,PHASE2,Columbia University,0.5555,2033.0,2033.1542754275426,2032.0,2034.0,2031,2036
NCT04850118,A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP,"PHASE2, PHASE3",Beacon Therapeutics,0.5601,2034.0,2034.347973576147,2033.0,2035.0,2031,2038
NCT06275620,A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN),PHASE2,Beacon Therapeutics,0.5724,2034.0,2034.037211740042,2033.0,2035.0,2031,2037
NCT05909488,Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II,"PHASE2, PHASE3",PT. Prodia Stem Cell Indonesia,0.5593,2034.0,2033.8376542106205,2033.0,2035.0,2031,2036
NCT06627179,Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene,PHASE2,Laboratoires Thea,0.5001,2035.0,2035.1151769646071,2034.0,2036.0,2032,2038
NCT06646289,A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP),PHASE2,"Janssen Research & Development, LLC",0.5062,2035.0,2034.9442907941525,2034.0,2036.0,2032,2038
NCT04611503,PDE6A Gene Therapy for Retinitis Pigmentosa,"PHASE1, PHASE2",STZ eyetrial,0.4378,2036.0,2036.1429876656007,2035.0,2037.0,2034,2039
NCT06292650,Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients,EARLY_PHASE1,Zhongmou Therapeutics,0.4328,2036.0,2036.4133548983364,2035.0,2038.0,2034,2039
NCT06912633,"Safety of a Single, Intravitreal Injection of 8.8M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)",PHASE2,"jCyte, Inc",0.5605,2036.0,2035.656735057984,2035.0,2037.0,2033,2039
NCT05203939,Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis,"PHASE1, PHASE2",Ocugen,0.48,2036.0,2036.1422916666668,2035.0,2037.0,2033,2039
NCT03374657,"A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa","PHASE1, PHASE2",Novartis Pharmaceuticals,0.4836,2036.0,2036.1511579818032,2035.0,2037.0,2034,2039
NCT06291935,Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene,PHASE1,ViGeneron GmbH,0.4246,2036.0,2036.1959491285916,2035.0,2037.0,2034,2039
NCT05147701,Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION,PHASE1,The Foundation for Orthopaedics and Regenerative Medicine,0.437,2036.0,2036.1318077803203,2035.0,2037.0,2034,2039
NCT04355689,Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome,"PHASE1, PHASE2","Nacuity Pharmaceuticals, Inc.",0.4917,2036.0,2036.1797844213952,2035.0,2037.0,2033,2039
NCT06565572,Antisense Oligonucleotide Treatment for PCARP Disease Due to Mutation in FLVCR1,EARLY_PHASE1,"University of Colorado, Denver",0.4857,2036.0,2036.194152769199,2035.0,2037.0,2033,2039
NCT03328130,Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene,"PHASE1, PHASE2",eyeDNA Therapeutics,0.4291,2036.0,2036.1552085760895,2035.0,2037.0,2033,2039
NCT03963154,Interventional Study of Implantation of hESC-derived RPE in Patients With RP Due to Monogenic Mutation,"PHASE1, PHASE2",Centre d'Etude des Cellules Souches,0.4784,2036.0,2036.140050167224,2035.0,2037.0,2033,2039
NCT06628947,A Phase II Study of Intravitreal KIO-301 in Patients with Late-stage Retinitis Pigmentosa,PHASE2,"Kiora Pharmaceuticals, Inc.",0.5552,2036.0,2035.6437319884726,2035.0,2037.0,2033,2039
NCT05282953,"A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients with Retinitis Pigmentosa and Choroideremia (ABACUS)","PHASE1, PHASE2","Kiora Pharmaceuticals, Inc.",0.4785,2036.0,2036.169487983281,2035.0,2037.0,2034,2039
NCT05805007,Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa,EARLY_PHASE1,Peking University Third Hospital,0.4274,2036.0,2036.2133832475433,2035.0,2037.0,2034,2039
NCT04123626,A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene,"PHASE1, PHASE2",ProQR Therapeutics,0.4368,2036.0,2036.1549908424909,2035.0,2037.0,2034,2039
NCT04284293,CNS10-NPC for the Treatment of RP,PHASE1,Cedars-Sinai Medical Center,0.4795,2036.0,2036.1511991657976,2035.0,2037.0,2034,2039
NCT03316560,Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations,"PHASE1, PHASE2",Beacon Therapeutics,0.4394,2036.0,2036.146563495676,2035.0,2037.0,2033,2039
NCT04517149,4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP),"PHASE1, PHASE2",4D Molecular Therapeutics,0.4777,2036.0,2036.1471634917311,2035.0,2037.0,2033,2039
NCT06492850,Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa,"PHASE1, PHASE2",Frontera Therapeutics,0.4366,2036.0,2036.4743472285845,2035.0,2038.0,2034,2039
NCT03999021,FIGHT-RP 1 Extension Study,PHASE1,Johns Hopkins University,0.4793,2036.0,2036.1287293970374,2035.0,2037.0,2034,2039
NCT03326336,Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa,"PHASE1, PHASE2",GenSight Biologics,0.4878,2036.0,2036.1660516605166,2035.0,2037.0,2033,2039
NCT04278131,BS01 in Patients With Retinitis Pigmentosa,"PHASE1, PHASE2",Bionic Sight LLC,0.4888,2036.0,2036.1518003273322,2035.0,2037.0,2034,2039
NCT05874310,Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa,EARLY_PHASE1,Frontera Therapeutics,0.4396,2036.0,2036.1665150136487,2035.0,2037.0,2034,2039
NCT05748873,Promising ROd-cone DYstrophy Gene TherapY,"PHASE1, PHASE2",SparingVision,0.4345,2036.0,2036.1611047180668,2035.0,2037.0,2034,2039
NCT01680510,The Effect of Oral Administration of 9-cis Î² Carotene Rich Powder of the Alga Dunaliella Bardawil,"PHASE1, PHASE2",Sheba Medical Center,0.4839,2036.0,2036.1663566852656,2035.0,2037.0,2033,2039
NCT06455826,MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby),PHASE1,PYC Therapeutics,0.4877,2037.0,2036.6401476317408,2035.0,2038.0,2034,2040
NCT06936787,"An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa",PHASE1,"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",0.4779,2037.0,2037.4639045825486,2036.0,2039.0,2035,2041
NCT06789445,A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO),"PHASE1, PHASE2",BlueRock Therapeutics,0.4761,2037.0,2037.356647763075,2036.0,2039.0,2034,2040
NCT06460844,Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION),PHASE1,"Ray Therapeutics, Inc.",0.4728,2037.0,2036.855752961083,2036.0,2038.0,2034,2040
NCT06891885,A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older with Retinitis Pigmentosa,"PHASE1, PHASE2","Sumitomo Pharma America, Inc.",0.4854,2037.0,2037.466419447878,2036.0,2039.0,2035,2041
NCT02018692,The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa,"PHASE1, PHASE2",Sheba Medical Center,0.4781,2037.0,2037.3396778916544,2036.0,2039.0,2034,2040
NCT06242379,Safety and Efficacy of Stem Cell Small Extracellular Vesicles in Patients With Retinitis Pigmentosa,"PHASE1, PHASE2",Mahidol University,0.4791,2037.0,2036.5900647046547,2035.0,2038.0,2034,2040
NCT06592131,BF844 Safety and Pharmacokinetic Study in Healthy Volunteers,PHASE1,EyeXCel Pty. Ltd.,0.4828,2037.0,2036.8529411764705,2036.0,2038.0,2034,2040
NCT06591793,Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa,"PHASE1, PHASE2",AAVantgarde Bio Srl,0.4423,2037.0,2036.678046574723,2036.0,2038.0,2034,2040
NCT06787482,"Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies","PHASE1, PHASE2",Ace Cells Lab Limited,0.4831,2037.0,2037.016973711447,2036.0,2038.0,2034,2040
NCT06952842,Safety and Efficacy of ZVS203e in the Treatment of Retinitis Pigmentosa Caused by RHO Gene Mutation,"PHASE1, PHASE2","Chigenovo Co., Ltd",0.4364,2038.0,2037.5407882676443,2036.0,2039.0,2035,2040
NCT02464436,Safety and Tolerability of hRPC in Retinitis Pigmentosa,"PHASE1, PHASE2",ReNeuron Limited,0.4831,2038.0,2037.6350652038916,2036.0,2039.0,2035,2041
NCT06319872,The Effects of Disulfiram (AntabuseÂ®) on Visual Acuity in Patients With Retinal Degeneration,PHASE1,University of Rochester,0.4379,2038.0,2037.5649691710437,2036.0,2039.0,2035,2041
NCT06852963,A Study of Two Doses of VP-001 Administered Intravitreally in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy Previously Treated with VP001,"PHASE1, PHASE2",PYC Therapeutics,0.4877,2038.0,2037.5860159934387,2036.0,2039.0,2034,2041
NCT01736059,Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy,PHASE1,"University of California, Davis",0.4779,2038.0,2037.6545302364511,2036.0,2039.0,2034,2041
